Ken Griffin Savara Inc Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Savara Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 40,700 shares of SVRA stock, worth $136,752. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,700

Previous 114,000 64.3%

Holding current value

$136,752

Previous $459,000 62.53%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.96 - $5.07 $614,520 - $786,772	155,182 Added 96.38%	316,189 $1.34 Million
Q2 2024 Aug 14, 2024	BUY	$3.66 - $5.34 $557,776 - $813,805	152,398 Added 1770.22%	161,007 $648,000
Q1 2024 May 15, 2024	SELL	$4.19 - $5.59 $675,976 - $901,840	-161,331 Reduced 94.93%	8,609 $42,000
Q4 2023 Feb 14, 2024	BUY	$3.18 - $4.9 $478,128 - $736,739	150,355 Added 767.7%	169,940 $798,000
Q3 2023 Nov 14, 2023	BUY	$2.97 - $3.88 $11,559 - $15,100	3,892 Added 24.8%	19,585 $74,000
Q2 2023 Aug 14, 2023	SELL	$1.69 - $3.24 $105,861 - $202,953	-62,640 Reduced 79.97%	15,693 $50,000
Q1 2023 May 15, 2023	BUY	$1.6 - $2.82 $62,112 - $109,472	38,820 Added 98.25%	78,333 $152,000
Q4 2022 Feb 14, 2023	BUY	$1.11 - $1.64 $23,779 - $35,133	21,423 Added 118.42%	39,513 $61,000
Q3 2022 Nov 14, 2022	SELL	$1.36 - $1.88 $19,628 - $27,134	-14,433 Reduced 44.38%	18,090 $28,000
Q2 2022 Aug 15, 2022	BUY	$1.1 - $1.58 $21,947 - $31,524	19,952 Added 158.71%	32,523 $49,000
Q1 2022 May 16, 2022	SELL	$1.05 - $1.36 $19,116 - $24,760	-18,206 Reduced 59.15%	12,571 $17,000
Q3 2021 Nov 15, 2021	SELL	$1.18 - $1.64 $13,852 - $19,251	-11,739 Reduced 27.61%	30,777 $42,000
Q2 2021 Aug 16, 2021	SELL	$1.51 - $2.29 $159,551 - $241,968	-105,663 Reduced 71.31%	42,516 $72,000
Q1 2021 May 17, 2021	BUY	$1.17 - $2.33 $142,666 - $284,113	121,937 Added 464.66%	148,179 $308,000
Q4 2020 Feb 16, 2021	SELL	$1.0 - $1.47 $445 - $654	-445 Reduced 1.67%	26,242 $30,000
Q3 2020 Nov 16, 2020	SELL	$1.09 - $2.21 $24,380 - $49,431	-22,367 Reduced 45.6%	26,687 $29,000
Q2 2020 Aug 14, 2020	SELL	$1.8 - $3.05 $31,368 - $53,152	-17,427 Reduced 26.21%	49,054 $122,000
Q1 2020 May 15, 2020	BUY	$1.91 - $4.08 $90,134 - $192,539	47,191 Added 244.64%	66,481 $141,000
Q4 2019 Feb 14, 2020	SELL	$0.71 - $4.91 $12,617 - $87,255	-17,771 Reduced 47.95%	19,290 $86,000
Q3 2019 Nov 14, 2019	SELL	$2.16 - $3.2 $166,363 - $246,464	-77,020 Reduced 67.51%	37,061 $98,000
Q2 2019 Aug 14, 2019	BUY	$2.37 - $11.7 $203,310 - $1 Million	85,785 Added 303.17%	114,081 $270,000
Q1 2019 May 15, 2019	SELL	$6.71 - $8.6 $8,347 - $10,698	-1,244 Reduced 4.21%	28,296 $0
Q4 2018 Feb 14, 2019	BUY	$6.27 - $10.92 $66,117 - $115,151	10,545 Added 55.51%	29,540 $223,000
Q3 2018 Nov 13, 2018	BUY	$10.49 - $12.87 $29,151 - $35,765	2,779 Added 17.14%	18,995 $0
Q2 2018 Aug 10, 2018	BUY	$8.55 - $13.76 $119 - $192	14 Added 0.09%	16,216 $0
Q1 2018 May 11, 2018	BUY	$8.99 - $14.95 $145,655 - $242,219	16,202 New	16,202 $149,000

Others Institutions Holding SVRA

# of Institutions

129

Shares Held

158M

Call Options Held

67.6K

Put Options Held

29.4K

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $383M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account